BCN Peptides   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Mediona Spain (1989)
Status: No NME R&D (1989)

Organization Overview

First Clinical Trial
2009
NCT00942851
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

brimonidine (alphagan) (1 trial)

somatostatin (1 trial)

Drugs in Phase 2 Trials (1)

acetyl hexapeptide-8 (1 trial)

Drugs in Phase 1 Trials (3)

apvac2 vaccine (1 trial)

poly-iclc (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharospasm (Phase 2)

Diabetic Retinopathy (Phase 3)

Dystonia (Phase 2)

Dystonic Disorders (Phase 2)

Glioblastoma (Phase 1)

Retinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6